OPEN SOURCE IMAGING CONSORTIUM (OSIC)

Building Better Evidence for Lung Disease Trials

From OSIC's global imaging foundation to OCRN's next-generation longitudinal intelligence network

THE CHALLENGE

WHY CURRENT TRIALS STRUGGLE

- Small patient populations
- Variable disease progression
- Difficult enrichment strategies
- Slow endpoints
- High development cost
- Pressure to reduce placebo exposure

CORE REALITY

In fibrotic lung disease, progression is clinically meaningful — but often inconsistently measured. That creates noise, delays, and uncertainty.

WHY THIS MATTERS NOW

External comparators, adaptive designs, and smarter trials all depend on fit-for-purpose longitudinal evidence.

WHAT THIS ENABLES

- ✓ Smaller smarter studies
- ✓ Faster learning cycles
- ✓ Better patient selection
- ✓ Stronger evidence decisions
- ✓ Reduced variability

Not a registry. Not a data dump.
A cooperative evidence engine.

A network of **60** global member and partner organizations.

ORGANIZATION OVERVIEW

SCIENCE TEAM

Dr. Kevin Brown
National Jewish Health | *Pulmonology Lead*

Dr. Jonathan Chung
University of California, San Diego | *OSIC Radiology Lead (US)*

Prof. David Barber
University College London | *Computational Science Lead*

Prof. Joseph Jacob
University College London Hospitals | *OSIC Radiology Lead (EU)*

MANAGEMENT TEAM

Elizabeth Estes
Executive Director

Carmela Wegworth
Director

INTRODUCING OCRN

OSIC Collaborative Research Network (OCRN)

A COOPERATIVE INFRASTRUCTURE DESIGNED TO GENERATE HARMONIZED LONGITUDINAL DATASETS FOR:

- Progression modeling
- Trial enrichment
- Endpoint intelligence
- Comparator feasibility
- Better development decisions

BUILT ON THE OSIC FOUNDATION

13,000+	Curated HRCT scans
Global	Multi-site cohorts
Structured	Imaging + clinical data
Proven	Publications + regulatory engagement

OSIC FOUNDATION 〉 **OCRN ENGINE** 〉 CLINICAL IMPACT



PLATFORM CASE VIEWER



PLATFORM FILTERS

CONTACT Carmela Wegworth, *OSIC Director* cwegworth@osicild.org **VISIT** OSICild.org **FOLLOW** 𝕏 in OSICild

OCRN LAUNCH PROGRAM

INITIAL FOCUS: ILA → ILD TRANSITION

- **5,000+** committed participants
- Multiple imaging timepoints
- Longitudinal follow-up
- Shared standards
- Adjudication workflows

FUTURE PROGRAMS

- Progressive Pulmonary Fibrosis
- Bronchiectasis
- Pulmonary Hypertension
- Rare respiratory disease

WHO WE SEEK TO WORK WITH

- Pharma
- Biotech
- Imaging AI
- Academic networks
- Translational partners

◀ **LET'S TALK**

OSICILD.ORG/POSTER2026

RIS Respiratory Innovation Summit

ATS 2026 May 15-16 **Orlando**